On this episode of Stock Movers:
- ABB Ltd. rallied after the company reported record order intake and profit margins that surpassed views, spurred by rising demand for automation tools and data center-driven investments in electrical grids. Orders surged 16% in the second quarter to $9.79 billion, lifted by a single $600 million deal for process-automation tools in the US, the Zurich-based industrial supplier said Thursday in a statement. ABB shares gained as much as 8.5%, the most intraday in over three months. 
- Legrand shares are trading at a record high this morning after jumping as much as 8.4% as the electrical device specialist posted organic growth well ahead of expectations in the second quarter and raised its outlook for the full year. Analysts cited strong demand for data centers in North America. 
- Novartis AG slumped after disappointing sales for its key psoriasis drug and the looming retirement of its respected finance chief overshadowed a modest outlook raise. Core operating profit will likely grow by a percentage in the low teens, the Swiss drugmaker said Thursday. New medicines made up for lackluster growth from the psoriasis treatment Cosentyx, which analysts pointed to as a concern. The shares fell as much as 2.8% in early Zurich trading, trimming this year’s gain to about 5%.

On this episode of Stock Movers: - ABB Ltd. rallied after the company reported record order intake and profit margins that surpassed views, spurred by rising demand for automation tools and data center-driven investments in electrical grids. Orders surged 16% in the second quarter to $9.79 billion, lifted by a single $600 million deal for process-automation tools in the US, the Zurich-based industrial supplier said Thursday in a statement. ABB shares gained as much as 8.5%, the most intraday in over three months. - Legrand shares are trading at a record high this morning after jumping as much as 8.4% as the electrical device specialist posted organic growth well ahead of expectations in the second quarter and raised its outlook for the full year. Analysts cited strong demand for data centers in North America. - Novartis AG slumped after disappointing sales for its key psoriasis drug and the looming retirement of its respected finance chief overshadowed a modest outlook raise. Core operating profit will likely grow by a percentage in the low teens, the Swiss drugmaker said Thursday. New medicines made up for lackluster growth from the psoriasis treatment Cosentyx, which analysts pointed to as a concern. The shares fell as much as 2.8% in early Zurich trading, trimming this year&rsquo;s gain to about 5%.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

 ABB Soars, Legrand Rises, Novartis Down  

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d9bf53fb-de98-4f5b-9835-b31d0087c5bd/transcript

Advertisement